Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) announced their collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies.  This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers.

Iotron Medical, a spin-out business of Iotron Industries, has been providing innovative solutions using electron beam technology for more than 25 years. CIIC is a startup company, producing medical radioisotopes using a novel linear accelerator-based method initially developed at the Canadian Light Source.

Cu-67 has long been known for its excellent properties for personalized cancer therapy, but has been extremely difficult to produce in sufficient quantity and purity using nuclear reactors or cyclotrons.

This novel production method for high purity Cu-67 is desired by researchers and pharmaceutical companies developing new drugs for a variety of cancers including neuroendocrine tumors, prostate and neuroblastoma.  When linked to a suitable targeting agent, Cu-67 could deliver highly localized radiation to tumor cells.

To read more please visit:

New Radioisotope for Cancer Therapy: A New Collaboration to produce copper-67-ISOTOPE INNOVATIONS

Source: ISOTOPE  INNOVATIONS